Bristol-Myers Squibb Co. (NYSE:BMY)

Top Analyst Upgrades and Downgrades: AMAG, Baidu, Cisco, GE, Honeywell, 3M, Salesforce, SunPower, UTC and More

This week has been a wild ride, but it has been a week full of recovery in stocks versus last week's panic selling with broken market efficiencies. The bull market ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

JPMorgan Likes Big Cap Pharmaceutical Stocks as Market Volatility Jumps

For years pharmaceuticals were one group considered good for “widows and orphans” as they provided safety and consistent and rising income via dividends. Then came the brutal 2016 political season wherein ...
Read Full Story »

Bristol-Myers Squibb Earnings, Trial Results Not Enough to Please Investors

Bristol-Myers Squibb Co. (NYSE: BMY) reported fourth-quarter and full-year 2017 results before markets opened Monday. For the quarter, the drug maker posted adjusted diluted earnings per share (EPS) of $0.68 ...
Read Full Story »

Disney, Tesla, Twitter and More Earnings Coming This Week

The broad markets posted their first major loss in a long time last week. Although the Dow and S&P 500 saw pullbacks of roughly 4% each over the course of ...
Read Full Story »

Major Pharma Short Interest Keeps Climbing

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

SunTrust Bullish on Blue Chip Large-Cap Pharmaceuticals: 4 to Buy Now

Some of last year's biggest laggards are starting to look like this year's winners out of the gate here in January. While health care was basically in line with the ...
Read Full Story »

Major Pharma Short Interest Takes a Plunge

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

20 More Biopharma Catalysts Coming in 2018

Over the course of 2017, biopharmaceutical companies more or less kept pace with the markets, ending up with a return just a little higher than the S&P 500. But going in ...
Read Full Story »

More and More Short Sellers Raising the Stakes in Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Short Sellers Can’t Make Up Their Minds on Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

2018 Outlook: Biotech Stocks Looking Strong for Value and Growth Investors

With 2017 coming to an end, investors are wondering how they should be investing for 2018 and beyond. At the start of December, the Dow was up just over 20% ...
Read Full Story »

Short Sellers Back Way Off Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Top Biopharma Events Coming by the End of 2017

As the markets continue to hit all-time highs, biotech and pharmaceutical companies have been part of these massive gains. There is a very positive sentiment in the health care sector ...
Read Full Story »

Short Sellers Hike Bets in Major Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »